PharmVar GeneFocus: CYP1A2 —Clinical Impact, Genetic Variation, and Updated Nomenclature
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70286 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Katalin Monostory und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2, Genetic Variation, Terminology as Topic, Pharmacogenetics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Foundation, SciLifeLab and Wallenberg National Program for Data-Driven Life Science, ERC Environment and Health Grant NEMESIS.
Abstract (Originalsprache)
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines. The activity of CYP1A2 varies significantly among individuals due to genetic and non‐genetic factors. This GeneFocus paper offers an overview of the functional significance of CYP1A2 in drug metabolism, CYP1A2 genetic variation, and presents the updated PharmVar star allele‐based nomenclature for CYP1A2 . Updates include revisions to previously defined star alleles to align with PharmVar standards, as well as the addition of novel star alleles, providing the pharmacogenetic community with a more comprehensive and high‐quality catalog of CYP1A2 genetic variation. We highlight that the common ‐163C>A (rs762551) variant, which previously defined CYP1A2*1F , is now the sole core variant for a newly established group of CYP1A2*30 alleles. Furthermore, the ‐163C>A variant, which has been associated with increased expression levels in smokers, has been found on various haplotypes in combination with one or more amino acid changing variants, each of which was assigned a unique star number (e.g., CYP1A2*13 , *21 , *24 , and *31 ). While all alleles containing ‐163C>A may have increased expression levels in smokers, it remains unknown whether the presence of one or more amino acids negates the effect of increased expression levels on CYP1A2 activity. Systematic nomenclature that comprehensively describes CYP1A2 variability is essential for future research aimed at assessing the relationship between CYP1A2 variation, drug metabolism, and the clinical utility of CYP1A2 pharmacogenetic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
- Semmelweis University, Budapest, Hungary.
- Department of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), Madrid, Spain.
- Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain.
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
- Base5 Genomics, Mountain View, California, USA.
ORCID-Profile: Katalin Monostory, Gonzalo Villapalos Garcia, Dora Koller, Solomon Adams, Chad A Bousman, Evangelia Eirini Tsermpini, Michelle Whirl-Carrillo, Amy J Turner, Volker M Lauschke, Mohamed Nagy, Erin C Boone, Teri E Klein, Pablo Zubiaur, Andrea Gaedigk
Förderung
- Novo Nordisk Foundation
- SciLifeLab and Wallenberg National Program for Data-Driven Life Science
- ERC Environment and Health Grant NEMESIS
- NIH HHS
- Swedish Research Council
- European Social Fund
- Robert Bosch Foundation
- Instituto Carlos III (ISCIII)
Zitieren
APA
Monostory, K., Villapalos Garcia, G., Koller, D., Adams, S., Bousman, C. A., Tsermpini, E. E., Whirl-Carrillo, M., Turner, A. J., Lauschke, V. M., Nagy, M., Boone, E. C., Klein, T. E., Zubiaur, P., & Gaedigk, A. (2026). PharmVar GeneFocus: CYP1A2 —Clinical Impact, Genetic Variation, and Updated Nomenclature. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70286
Vancouver
Monostory K, Villapalos Garcia G, Koller D, Adams S, Bousman CA, Tsermpini EE, et al. PharmVar GeneFocus: CYP1A2 —Clinical Impact, Genetic Variation, and Updated Nomenclature. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70286
BibTeX
@article{Monostory2026,
author = {Monostory, Katalin and Villapalos Garcia, Gonzalo and Koller, Dora and Adams, Solomon and Bousman, Chad A and Tsermpini, Evangelia Eirini and Whirl-Carrillo, Michelle and Turner, Amy J and Lauschke, Volker M and Nagy, Mohamed and Boone, Erin C and Klein, Teri E and Zubiaur, Pablo and Gaedigk, Andrea},
title = {PharmVar GeneFocus: CYP1A2 —Clinical Impact, Genetic Variation, and Updated Nomenclature},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70286}
}
EUVIMED